ALNY Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: August 06, 2025

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for Alnylam Pharmaceuticals Inc (ALNY)

Based on 39 analysts giving stock ratings to Alnylam Pharmaceuticals Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
21
Buy
55
Hold
21
Sell
0
Strong Sell
3
Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc. Stock Analysis ALNY

United States Health Care Large Cap Report:
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Read More

Alnylam Pharmaceuticals Inc (ALNY) Chart

Alnylam Pharmaceuticals Inc (ALNY) vs CBOE Volatility Index (VIX) Comparative Returns

Analysis of Alnylam Pharmaceuticals Inc (ALNY) stock performance compared to the broader market (CBOE Volatility Index (VIX)) across multiple timeframes.

YTD Performance
  • Alnylam Pharmac... (ALN...) 92.75%
  • CBOE Volatility Index (VIX) -16.43%
Alnylam Pharmac... Outperformed CBOE Volatility Index (VIX) by 109.18%
1Y Performance
  • Alnylam Pharmac... (ALN...) 64.14%
  • CBOE Volatility Index (VIX) -7.35%
Alnylam Pharmac... Outperformed CBOE Volatility Index (VIX) by 71.49%
3Y Performance
  • Alnylam Pharmac... (ALN...) 113.93%
  • CBOE Volatility Index (VIX) -44.68%
Alnylam Pharmac... Outperformed CBOE Volatility Index (VIX) by 158.61%
5Y Performance
  • Alnylam Pharmac... (ALN...) 242.93%
  • CBOE Volatility Index (VIX) -36.85%
Alnylam Pharmac... Outperformed CBOE Volatility Index (VIX) by 279.78%

Key Statistics of Alnylam Pharmaceuticals Inc (ALNY)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$450.50$454.26

Today's Open

$452.83

Volume

971.76K

P/E Ratio (TTM)

-

52 Week Range

$205.87$333.70

Market Cap

59.53B

Avg. Volume

1.14M

Dividend Yield

-

Financial Metrics & Statements of Alnylam Pharmaceuticals Inc (ALNY)

Super Investors Invested in Alnylam Pharmaceuticals Inc (ALNY)

Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.

lock-image

FAQ's for Alnylam Pharmaceuticals Inc (ALNY)

Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.